The estimated Net Worth of Joseph L Herring is at least $4.85 Миллион dollars as of 3 November 2016. Mr. Herring owns over 267 units of Henry Schein stock worth over $51,427 and over the last 10 years he sold HSIC stock worth over $4,485,597. In addition, he makes $317,400 as Independent Director at Henry Schein.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Herring HSIC stock SEC Form 4 insiders trading
Joseph has made over 2 trades of the Henry Schein stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 267 units of HSIC stock worth $41,179 on 3 November 2016.
The largest trade he's ever made was selling 36,876 units of Henry Schein stock on 25 February 2015 worth over $4,485,597. On average, Joseph trades about 2,653 units every 44 days since 2015. As of 3 November 2016 he still owns at least 767 units of Henry Schein stock.
You can see the complete history of Mr. Herring stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Joseph Herring biography
Joseph L. Herring serves as Independent Director of the Company. From 2005 to 2015, From 2005 to 2015, Mr. Herring served as Chief Executive Officer of Covance Inc., a drug development services company, and as Chairman of the Board of Directors of Covance from 2006 until its acquisition by Laboratory Corporation of America, Inc. in 2015. Mr. Herring previously served in several executive roles with Covance, including President and Chief Operating Officer, President of Early Development Services and Corporate Vice President and General Manager for its North American Preclinical Operations. Prior to joining Covance, Mr. Herring held a variety of senior leadership positions with Caremark International and American Hospital Supply Corporation over the course of his 19 years with the combined companies. The Company’s Board of Directors values Mr. Herring’s more than 35 years of experience in the healthcare industry. Mr. Herring also brings to the Company’s Board of Directors comprehensive knowledge in pharmaceuticals, management, sales and corporate governance matters. Mr. Herring currently serves on the nonprofit board for University Medical Center of Princeton and previously served on the board of the Association of Clinical Research Organizations, of which he served as chairman. During the past five years, Mr. Herring served as a director of Covance Inc. and Team Health Holdings Inc.
What is the salary of Joseph Herring?
As the Independent Director of Henry Schein, the total compensation of Joseph Herring at Henry Schein is $317,400. There are 13 executives at Henry Schein getting paid more, with Stanley Bergman having the highest compensation of $14,422,900.
How old is Joseph Herring?
Joseph Herring is 64, he's been the Independent Director of Henry Schein since 2016. There are 14 older and 16 younger executives at Henry Schein. The oldest executive at Henry Schein Inc. is Barry Alperin, 79, who is the Independent Director.
What's Joseph Herring's mailing address?
Joseph's mailing address filed with the SEC is C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE, NY, 11747.
Insiders trading at Henry Schein
Over the last 22 years, insiders at Henry Schein have traded over $272,732,340 worth of Henry Schein stock and bought 23,637 units worth $1,414,559 . The most active insiders traders include Stanley M Bergman, Norman S Matthews и Deborah Derby. On average, Henry Schein executives and independent directors trade stock every 21 days with the average trade being worth of $1,074,342. The most recent stock trade was executed by Lorelei Mc Glynn on 6 September 2024, trading 21,035 units of HSIC stock currently worth $1,457,726.
What does Henry Schein do?
henry schein, inc. is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners. the company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. a fortune 500® company and a member of the s&p 500® and nasdaq 100® indexes, henry schein employs more than 18,000 team schein members and serves more than one million customers. the company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. henry schein operates through a centralized and automated distribution network, with a selection of more than 100,000 branded products and henry schein private-brand products in stock, as well as more than 150,000 additional products available as special-order items. the company also offers its customers exclusive, innovative technology solutions, including practice
What does Henry Schein's logo look like?
Complete history of Mr. Herring stock trades at Henry Schein и Labcorp
Henry Schein executives and stock owners
Henry Schein executives and other stock owners filed with the SEC include:
-
Stanley Bergman,
Chairman of the Board, Chief Executive Officer -
Stanley M. Bergman,
Exec. Chairman & CEO -
Steven Paladino,
Chief Financial Officer, Executive Vice President, Director -
Gerald Benjamin,
Chief Administrative Officer, Executive Vice President, Director -
James Breslawski,
President, Vice Chairman of the Board, Director -
Mark Mlotek,
Chief Strategic Officer, Executive Vice President, Director -
James P. Breslawski,
Exec. Vice Chairman & Pres -
Gerald A. Benjamin,
Exec. VP, Chief Admin. Officer & Exec. Director -
Steven Paladino,
Exec. VP, CFO & Exec. Director -
Mark E. Mlotek,
Exec. VP, Chief Strategic Officer & Exec. Director -
Michael Racioppi,
Senior Vice President, Chief Merchandising Officer -
Philip Laskawy,
Lead Independent Director -
Barry Alperin,
Independent Director -
Joseph Herring,
Independent Director -
Kurt Kuehn,
Independent Director -
Bradley Sheares,
Independent Director -
Carol Raphael,
Independent Director -
Anne Margulies,
Independent Director -
Elizabeth Rekow,
Independent Director -
Shira Goodman,
Independent Director -
Paul Brons,
Independent Director -
James Mullins,
Senior Vice President of Global Services -
Rene Willi,
President, Global Dental Surgical Group -
David Brous,
President, Strategic Business Units Group and Asia Pacific & Brazil Dental -
Steven Kess,
President of the Santa Fe Group -
Carolynne Borders,
Vice President - Investor Relations -
Jonathan Koch,
Senior Vice President and Chief Executive Officer, Global Dental Group and Interim Chief Executive Officer, Henry Schein One -
Michael Ettinger,
Senior Vice President - Corporate and Legal Affairs, Chief of Staff, Secretary -
Lorelei McGlynn,
Chief Human Resource Officer -
Walter Siegel,
Senior Vice President, General Counsel -
Christopher Pendergast,
Senior Vice President, Chief Technology Officer -
Brad Connett,
President - Henry Schein's U.S. Medical Group -
Olga Timoshkina,
VP of Corp. Fin., Chief Accounting Officer & Corp. Controller -
Michael Saul Ettinger,
Exec. VP & COO -
Ronald N. South,
Sr. VP & CFO -
John Lee,
VP of Global Compensation & Benefits -
Walter Siegel,
Chief Legal Officer -
Graham Stanley,
VP of Investor Relations & Strategic Fin. Project Officer -
Christopher Pendergast,
Sr. VP & CTO -
Ronald South,
Chief Accounting Officer & VP of Corp. Fin. -
Paul Rose,
SVP, Global Supply Chain -
David Mc Kinley,
President, Medical Group -
Donald J Kabat,
Director -
Karen Prange,
EVP&CEO Gl.AH.Med.Den.Sur.Grp -
Lawrence S Bacow,
Director -
Robert Minowitz,
President, Int'l Dental Group -
E Dianne Rekow,
Director -
Peter M. Mc Carthy,
Pres., Global Animal Health -
Bridget A Ross,
President, Global Medical Grp -
James A. Harding,
Chief Technology Officer -
Mohamad Ali,
-
Deborah Derby,
-
Michael Zack,
Senior Vice President -
Larry Gibson,
Executive V.P. and CTO -
Irving Shafran,
Director -
Margaret A Hamburg,
Director -
Marvin Schein,
-
Pamela Joseph,
Director -
Stanley Komaroff,
Senior Advisor -
Lonnie Shoff,
Pres., Global Healthcare Spec. -
Norman S Matthews,
Director -
Louis W Sullivan,
Director -
Karyn Mashima,
Director -
Leonard A David,
Vice President -
Reed Vaughn Tuckson,
-
Scott Philip Serota,
-
Carole T Faig,
-
Ronald N. South,
SVP & Chief Financial Officer